ArticleJournal of the Egyptian National Cancer Institute2026
Oncological safety and short-term aesthetic outcome of extreme oncoplasty for breast cancer.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor individuals with breast cancer, oncoplastic breast surgery (OBS), is considered an innovative technique of breast conservative surgery (BCS), has emerged as the recommended substitute for mastectomy. BCS and mastectomy have been shown to have comparable locoregional control and overall survival in randomized trials. In order to ensure oncological safety and improved aesthetic results, Extreme Oncoplasty, a development in the field of oncoplasty, has given hope for patient to achieve ultimate conservation before mastectomy. PATIENTS AND
methodsFrom October 2021 to May 2023, fifty patients fulfilling our eligibility criteria underwent extreme oncoplasty for breast cancer have been included in the current study. Reduction mammoplasty (superomedial, superiolateral and inferior pedicle), upper matrix rotational flap, and Passot’s technique were our adopted surgical techniques. One year following surgery, short-term aesthetic results were objectively assessed using Breast Cancer Conservative Treatment (BCCT) core program.
resultsOur study has included 50 cases with age range from 35 to 61 years (mean 52.28 ± 6.3). 38 patients presented with tumor size more than 5 cm not responding to the neoadjuvant therapy for downsizing and 12 patients presented with multifocal lesions. The total aesthetic results according to the BCCT core software were good in 52% (26 cases), fair in 34% (17 cases) and poor in 14% (7 cases). Our study has reported two cases of recurrence (4%) one year after surgery which were managed via mastectomy.
conclusionAccording to short-term follow-up, extreme oncoplasty is oncologically safe. To provide patients with advanced or multifocal breast cancer with extreme oncoplasty as a viable alternative, large-scale research are needed to validate these first findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.